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Cardiolipin (CL) is a dimeric phospholipid with critical roles
in mitochondrial bioenergetics and signaling. Recently, inhibi-
tion of the release of oxidized fatty acyl chains from CL by
the calcium-independent phospholipaseA2 (iPLA2)-selective
inhibitor (R)-BEL suggested that iPLA2 is responsible for the
hydrolysis of oxidizedCL and subsequent signalingmediated by
the released oxidized fatty acids. However, chemical inhibition
by BEL is subject to off-target pharmacologic effects. Accord-
ingly, to unambiguously determine the role of iPLA2 in the
hydrolysis of oxidized CL, we compared alterations in oxidized
CLs and the release of oxidized aliphatic chains from CL in
experiments with purified recombinant iPLA2, germ-line
iPLA2/ mice, cardiac myocyte-specific iPLA2 transgenic
mice, and wild-type mice. Using charge-switch high mass accu-
racy LC-MS/MSwith selected reactionmonitoring and product
ion accurate masses, we demonstrated that iPLA2 is the major
enzyme responsible for the release of oxidized aliphatic chains
from CL. Our results also indicated that iPLA2 selectively
hydrolyzes 9-hydroxy-octadecenoic acid in comparison to
13-hydroxy-octadecenoic acid from oxidized CLs. Moreover,
oxidative stress (ADP, NADPH, and Fe3) resulted in the ro-
bust production of oxidized CLs in intact mitochondria from
iPLA2/ mice. In sharp contrast, oxidized CLs were readily
hydrolyzed in mitochondria from wild-type mice during oxida-
tive stress. Finally, we demonstrated that CL activates the
iPLA2-mediated hydrolysis of arachidonic acid from phos-
phatidylcholine, thereby integrating the production of lipid
messengers from different lipid classes in mitochondria. Col-
lectively, these results demonstrate the integrated roles of CL
and iPLA2 in lipid second-messenger production and mito-
chondrial bioenergetics during oxidative stress.
Cardiolipin (CL)3 is a unique doubly charged phospholipid
that is nearly exclusively present in the mitochondrial mem-
brane where it is synthesized and plays an important role in
mitochondrial bioenergetics and signaling (1–7). The impor-
tance of CL in mitochondrial function is underscored in Barth
Syndrome where alterations in the tafazzin gene result in
pathologic changes in CL aliphatic chain composition due to
defective CL remodeling precipitating a dilated cardiomyopa-
thy, skeletal muscle weakness, and neutropenia (8–13).
The predominant molecular species of cardiolipin in heart,
skeletal muscle, and liver is tetralinoleoyl cardiolipin (TLCL),
which is produced from nascent CL (largely 16:0–18:1) by
remodeling catalyzed by the transacylase tafazzin as well as
other enzymes (14–17). Tetralinoleoyl CL contains four bis-
allylic protons that are susceptible toH radical abstraction pro-
ducing a resonance-stabilized bis-allylic radical that, in the
presence of molecular oxygen, produces a cadre of oxidized
cardiolipin hydroperoxides (18–20). Furthermore, cardiolipin
content andmolecular species composition is markedly altered
in both type 1 and type 2 models of diabetes which precipitates
mitochondrial bioenergetic dysfunction (21–22).
In the canonical pathway of lipid 2nd messenger generation,
polyunsaturated fatty acids such as arachidonic acid (AA) and
docosahexaenoic acid (DHA) are released from choline and
ethanolamine phospholipids by cytosolic phospholipase A2
(cPLA2) and subsequently oxidized to bioactive eicosanoids
and docosanoids by a diverse array of cyclooxygenases, lipoxy-
genases, and cytochromes P450s (23–26). Mitochondria
occupy30% of the volume of myocardium (27), and60% of
myocardial phospholipids are present in the mitochondrial
compartment (28). The close spatial proximity of cardiolipin to
mitochondrial sites of generation of reactive oxygen species
(ROS) in conjunctionwith themultiple bis-allylic protons inCL
render it susceptible to oxidation in the mitochondrial com-
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partment during oxidative stress (29). Studies by Kagan and
co-workers (30) have identified hydrolysis of oxidized CLs
(oxCL) as amitochondrial source of released oxidized fatty acid
lipid 2nd messengers from oxCL. The enzyme responsible for
the release of the oxidized acyl chains in CL is inhibited by
R-BEL. These results suggest that iPLA2 is a potential media-
tor of oxidized fatty acid release and signaling from oxCL (30,
31). However, BEL was first identified as a chymotrypsin inhib-
itor (32) and has been shown to also inhibit other esterases (33).
Hydrolysis of BEL by iPLA2 also generates a diffusible bromom-
ethyl keto acid that can alkylate thiol groups present in proteins
containing reactive cysteine residues (34). Thus, to establish the
role of iPLA2 in the release of aliphatic chains from CL, it is
necessary to use the specificity inherent in genetic ablation.
Accordingly, we utilized purified recombinant human iPLA2,
cardiac myocyte-specific iPLA2 transgenic mice, and germ-
line iPLA2 knock-out mice we generated to demonstrate that
iPLA2 is the major enzyme responsible for lipid 2nd messen-
ger release from oxidized CLs during oxidative stress by multi-
ple criteria both in vitro and in vivo.
Previously we generated germ-line iPLA2/mice by elim-
inating the active site of the enzyme. The phenotype of the
iPLA2/ mice is remarkable for 1) growth retardation, 2)
decreased exercise endurance, 3) compromised thermal adap-
tion to cold, and 4) inability to compensate for increased car-
diac stress after hemodynamic overload by thoracic aortic con-
striction. Moreover, shotgun lipidomic analysis of myocardial
tissue from iPLA2KOmice revealed a 15%decrease in total CL
content and a 33% decrease in tetra-18:2 CL molecular species
in comparison to theirWT littermates. These alterations in CL
content andmolecular species were accompanied by decreased
Complex 4 function. Importantly, alterations in CL remodeling
were identified in brain, which demonstrated reduced CL con-
tent with an increase in nascent CL molecular species (e.g.
enrichment of nascent 16:0 and 18:1 fatty acids), again demon-
strating the role of iPLA2 in CL remodeling. The inability of
iPLA2 KOmice to adapt to the absence of iPLA2 and result-
ant reduced mitochondrial function identifies the importance
of iPLA2 in maintaining CL content and molecular species
alterations in mitochondrial bioenergetics and organismal
function. Collectively, these results underscore the pivotal role
of iPLA2 in the remodeling of CL in mitochondria (35).
Previously, we have also generated cardiac myocyte-specific
iPLA2 transgenic mice, which possess multiple remarkable
cardiac mitochondrial phenotypes including: 1) a markedly
decreased content of total myocardial lipids, 2) a diminished
density of mitochondrial cristae, 3) accumulation of triglycer-
ides during caloric restriction, and 4) fasting-induced hemo-
dynamic dysfunction. These results further substantiate the
importance of iPLA2 in maintaining mitochondrial CL con-
tent and molecular species to facilitate physiologic adaptations
of mitochondria to external perturbations requiring efficient
bioenergetic function and energy storage (36).
In early work, we demonstrated that vesicles containing
intrinsic negative charge are rapidly hydrolyzed inmyocardium
in comparison to neutral or positively charged phospholipid
bilayers (37). Thus, we hypothesized that the double negatively
charged cardiolipin would also activate iPLA2-mediated hy-
drolysis of PC to release free fatty acids such as arachidonic
acid, which can then be further metabolized to downstream
eicosanoids. This hypothesis was explored through mass spec-
trometric analyses of PC/CL unilamellar vesicles hydrolyzed by
iPLA2 as a model system to explore the integration of fatty
acid signaling emanating frommitochondrial CL and PC pools.
Thus, mitochondrial signaling processes can be integrated dur-
ing normal physiologic function but would be susceptible to
maladaptive changes in production of oxidized aliphatic chains
during oxidative stress resulting in iPLA2-mediated patho-
logic dysfunction. Herein, we demonstrate that purified recom-
binant iPLA2 releases oxidized aliphatic chains from oxCLs,
that iPLA2 is highly selective for the release of 9-HODE over
13-HODE in calcium-stimulated mitochondrial homogenates,
and that iPLA2 is responsible for the release of oxidized lino-
leic acid lipid mediators in intact mitochondria subjected to
oxidative stress. We also demonstrate the important role of CL
in promoting the release of arachidonic acid and 2-AA LPC
from choline glycerophospholipids emphasizing the impor-
tance of iPLA2 in integratingmitochondrial lipid 2ndmessen-
ger signaling from discrete phospholipid classes.
Results
Hydrolysis of cardiolipin by recombinant iPLA2
To determine if recombinant human iPLA2 could hydro-
lyze cardiolipin,we incubated the purified enzymewith a binary
mixture of phospholipids in small unilamellar vesicles. Vesicles
composed of TLCL as guest and 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphocholine (PAPC) as host (6M and 54M,
respectively) were prepared by co-sonication. After incubation
of purified recombinant iPLA2 with TLCL/PAPC vesicles,
reaction products were extracted with chloroform/methanol/
water (1:1:1, v/v/v) and analyzed by LC-MS/MS as described
under “Experimental procedures.” Representative extracted
ion chromatograms of the reaction products produced during
iPLA2-catalyzed hydrolysis of TLCL are shown in Fig. 1A.
Accurate mass analyses and chromatographic elution profiles
led to the assignments of reaction products as linoleic acid,
monolysocardiolipin, and dilysocardiolipin. Initial rate analysis
(Fig. 1B) demonstrated that the rate of iPLA2-catalyzed
release of linoleic acid from TLCL guest is18 nmol/mgmin.
Tandemmass spectrometric analysis of the reaction products
generated by iPLA2-catalyzed hydrolysis of cardiolipin
To unambiguously substantiate the identities of products
derived from the reaction of iPLA2 with TLCL, MS2 analyses
of the hydrolysis products of TLCL were performed. Fragmen-
tation of the major hydrolytic product present atm/z 592 (cor-
responding to monolysocardiolipin, the chromatographic peak
at 17min in Fig. 1A) resulted in twomajor product ions present
at m/z 279 (18:2 carboxylate anion) and m/z 905 (18:2 carbox-
ylate anion loss of [M-2H]2), arising from the loss of fatty
acyl chains as carboxylate anions (Fig. 2A). In addition, tandem
mass spectra of the ion atm/z 592 also gave rise to product ions
present at m/z 461 (18:2-ketene resulting from the loss of
[M-2H]2), m/z 643 (18:2-ketene loss plus 18:2 carboxyl
anion loss of [M-2H]2), andm/z 415 (linoleoylglycerol phos-
phate) (Fig. 2A). Next, analysis of the fragmentation products of
iPLA2 hydrolyzes oxidized cardiolipin
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the hydrolysis product atm/z 461 (corresponding to dilysocar-
diolipin, the chromatographic peak at 14 min in Fig. 1A) was
examined. The results identified product ions atm/z 279 (18:2
carboxylate anion), m/z 645 (18:2 carboxyl anion resulting
from loss of [M-2H]2), and m/z 330 (18:2-ketene loss of
[M-2H]2) (Fig. 2B). Collectively, these fragmentation pat-
terns are consistent with the previously elucidated major frag-
mentation pathways for the [M-2H]2 ions of cardiolipin (Fig.
2C) (38) and substantiate the identities of the products as
monolysocardiolipin and dilysocardiolipin.
Cardiolipin-mediated activation of iPLA2
Because iPLA2 is an important enzymic mediator of the
release of fatty acids and lysophospholipids frommitochondrial
membrane phospholipids (39), we sought to determine if
iPLA2 activity was modulated by cardiolipin. To this end, the
specific activities of iPLA2 were measured with PAPC vesicle
hosts containing incremental mole fractions of cardiolipin
guest. Incubations of vesicles composed of 0M, 3M, 6M, or
12 M TLCL in 60 M PAPC (representative of the CL content
in the mitochondrial inner membrane) were performed with
purified recombinant iPLA2 as described under “Experimen-
tal procedures.” The phospholipase activity of iPLA2 with
PAPC substrate was strongly activated by the presence of car-
diolipin with substantial effects elicited at 5 mol % CL (10-fold
activation), whereas incubations with 20 mol % CL increased
iPLA2-mediated PAPC hydrolysis by 15-fold (Fig. 3, A and B).
In these reactions, cardiolipin was also hydrolyzed as demon-
strated by the release of linoleic acid and the concomitant gen-
eration of monolysocardiolipin. As the mole fraction of TLCL
guest in host PC vesicles increased, the hydrolysis of bothTLCL
and PC increased (Fig. 3C). In addition, experiments using
monolysocardiolipin with its double negative charge as guest in
PC vesicles similarly activated iPLA2 hydrolysis of TLCL guest
and PC host vesicles (Fig. 3D). Because both arachidonic
acid and 2-arachidonoyl-lysophosphatidylcholine (2-AA-LPC)
released by iPLA2 can serve as substrates for cyclooxygenase-2
(COX-2) and 15-lipoxygenase (15-LOX) oxidation (40), these
results identify the potential role of cardiolipin in regulating the
synthesis of oxidized lipid 2nd messengers.
The abundance of oxidized cardiolipins was increased by
genetic ablation of iPLA2
To determine the role of iPLA2 on the content of oxidized
cardiolipins in cardiac myocytes, we quantified the amount of
oxidized cardiolipins in WT and iPLA2/myocardial tissue
from 6-month-old mice. To gain access into the extremely low
abundance regime of oxidized cardiolipins, crude lipid extracts
fromWTandKOhearts were initially purified by an aminopro-
pyl solid phase extraction column (to separate acidic phospho-
lipids from total lipids) and analyzed by LC-MS in the negative
ion mode as described under “Experimental procedures.” The
results demonstrated that iPLA2/ myocardium contains
more oxidized cardiolipin in comparisons with wild-type mice
(Fig. 4A). Three predominant intrinsic oxidized cardiolipins
identified in these analyses include TLCL-OH, TLCL-OOH,
and 18:2–18:2–18:2–22:6 CL-OH (Fig. 4B).
To substantiate the proposedmolecular species assignments,
product ions resulting from the three molecular species were
generated by collision-induced dissociation (CID) and analyzed
by full mass scanning. As shown in Fig. 4C, the ion present at
m/z 731 has a similar tandem mass spectrum as non-oxidized
cardiolipin, whereas the only differences present in all fragment
pairs are M and M16 ions for singly charged ions or M and
M8 for doubly charged ions. These results indicate that the
ion present at m/z 731 is mono-oxygenated. Accordingly, the
presence of these fragment ions substantiates the molecular
identity of the ion present at m/z 731 as TLCL-OH. Similarly,
the ions present at m/z 739 and m/z 755 were identified as
TLCL-OOH and as 18:2–18:2–18:2–22:6 CL-OH, respectively
(Fig. 4,D and E). Collectively, the increased content of oxidized
molecular species of cardiolipins in iPLA2/suggests that
iPLA2 is a prominent enzymatic mediator of the hydrolysis of
oxidized cardiolipins in myocardium.
Determination of themolecular species of oxidized fatty acyl
chains in oxidized cardiolipin
To determine themolecular species of the oxidized fatty acyl
chains in oxidized cardiolipins, the oxidized cardiolipins from
wild-type mouse myocardium were purified and hydrolyzed by
phospholipase A1 from Thermomyces lanuginosus and phos-
Figure 1. iPLA2mediatedhydrolysis of cardiolipin toproduce free fatty
acids, monolysocardiolipin, and dilysocardiolipin. A, extracted ion chro-
matogram of iPLA2-hydrolyzed products from TLCL. Purified recombinant
iPLA2 (6 g) was incubated with 6 M TLCL (10 mol%) and 54 M PAPC at
37 °C for 15min in 20mMHEPES, pH7.2, containing 2mMEGTAand1mMDTT.
The reaction was terminated by adding chloroform/methanol (1:1, v/v), and
the resultant lipids were extracted in the presence of internal standards (14:
0–14:0–14:0monolysocardiolipin (mCL), d4-16:0-FFA). The chloroformphase
was separated and dried under a nitrogen stream. The dried residue was
reconstituted in methanol, separated on a C18 HPLC column, and analyzed
using a LTQ-Orbitrap mass spectrometer with a mass resolution of 30,000 at
m/z400and in thenegative ionmode. Theextracted ionchromatogramsof
linoleic acid (279.2325), monolysocardiolipin (592.3632), and dilysocardioli-
pin (461.2479) are as shown. B, production of linoleic acid (LA) and monoly-
socardiolipin (mCL) from TLCL hydrolysis by iPLA2 at different incubation
times. Values are the average of three independent preparations S.E.
iPLA2 hydrolyzes oxidized cardiolipin
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Figure 2. Identificationofmonolysocardiolipin anddilysocardiolipin released fromTLCLbypurified recombinant human iPLA2. The lysocardiolipins
generatedby iPLA2-mediatedhydrolysis of TLCLwere separatedonaC18HPLCcolumnandanalyzedbymass spectrometry. Fragmentationswereperformed
in an LTQ ion trapwith a collision energy of 30 eV, and the resultant fragment ionswere detected inOrbitrapwith amass resolution of 30,000 atm/z 400 and
a mass accuracy within 5 ppm. A, MS2 spectra of parent ion [M-2H]2 atm/z 592 (corresponding monolysocardiolipin, the chromatographic peak at 17 min
in Fig. 1A). Themajor fragment ions atm/z 279 andm/z 905 resulting from 18:2 carboxyl anion loss of [M-2H]2 are characteristic for monolysocardiolipin. B,
MS2 spectra of the parent ion [M-2H]2 atm/z 461 (corresponding dilysocardiolipin, the chromatographic peak at 14min in Fig. 1A). Themajor fragment ions
atm/z 279 andm/z 643 resulting from 18:2 carboxyl anion loss of [M-2H]2 are characteristic for dilysocardiolipin. C, scheme of the fragmentation pathways
of doubly charged cardiolipin.
Figure 3. Cardiolipin activated iPLA2 phospholipase activity resulting in increased release of free fatty acids and lysolipids. A–C, effect of increasing
CL content on PAPC and CL hydrolysis. Purified recombinant iPLA2 (6 g) was incubated with PAPC SUVs (60 M) containing either 0, 3, 6, or 12 M TLCL (0,
5, 10, 20 mol % of PAPC) at 37 °C for 15 min in 20 mM HEPES, pH 7.2, containing 2 mM EGTA and 1 mM DTT. The reaction was terminated by adding
chloroform/methanol (1:1, v/v), and the resultant lipidswere extracted in the presence of internal standards (17:0-LPC andd4-16:0-FFA). The chloroformphase
was separated and dried under nitrogen stream. The dried residue was reconstituted in methanol, separated on a C18 HPLC column, and analyzed by an
LTQ-Orbitrapmass spectrometer. The palmitic acid and arachidonic acid released fromPAPC (A), lysophosphatidylcholine released fromPAPC (B), and linoleic
acid and monolysocardiolipin (mCL) released from TLCL (C) were quantified. D, purified recombinant iPLA2 (6 g) was incubated with 6 M TLCL or 6 M
18:2–18:2–18:2monolysocardiolipin and 60MPAPC at 37 °C for 15min in 20mMHEPES, pH 7.2, containing 2mMEGTA and 1mMDTT. The lipids released from
PAPC were quantified and comparatively shown. Values are the average of three independent preparations S.E.
iPLA2 hydrolyzes oxidized cardiolipin
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pholipase A2 from porcine pancreas. This process hydrolyzed
all of the fatty acyl chains fromoxidized cardiolipin as described
under “Experimental procedures.” The released oxidized poly-
unsaturated fatty acids were extracted, derivatized with N-(4-
aminomethylphenyl)-pyridinium (AMPP), and analyzed by
LC-MS/MS. As shown in Fig. 5, the major oxidized fatty acyl
chains in myocardial oxidized cardiolipin are 9-HODE,
13-HODE, 10-hydroxydocosahexaenoic acid (10-HDHA), and
11-hydroxydocosahexaenoic acid (11-HDHA). The retention
times and selected reaction transitions of the oxidized fatty
acids frommyocardial oxidized cardiolipin (left panel) are iden-
tical to those of authentic standards (right panel) (Fig. 5).
Hydrolysis of oxidized cardiolipin by purified recombinant
iPLA2
To determine the capacity of iPLA2 to hydrolyze oxidized
cardiolipin, we oxidized TLCL by cytochrome c treatment in
vitro as described under “Experimental procedures” and gener-
ated vesicles containing oxCL as guest in host PAPC mem-
branes. Incubations with purified recombinant iPLA2 were
Figure 4. Genetic ablation of iPLA2 caused the accumulation of oxidized cardiolipin. A, oxidized cardiolipin levels (i.e. the sum of the three
predominant oxidized CL species) inwild-type and iPLA2
/myocardium tissue. Freshly isolated heart tissues fromwild-type and iPLA2
/micewere
flash-frozen in liquid nitrogen, homogenized using a Teflon pestle grinder, and extracted in the presence of TMCL internal standard. The extracts were
purified by aminopropyl solid phase extraction column and analyzed by LC-MS/MS in negative ionmode as described under “Experimental procedures.”
Values are the average of four independent preparations S.E. *, p 0.05. B, mass spectrum of oxidized cardiolipin fromwild-type mouse myocardium
tissue. C–E, aminopropyl solid phase extraction purified lipid extract (from two mouse hearts) was separated on a C18 HPLC column, and the fraction
containing oxidized cardiolipin was collected and dried. The dried residue was reconstituted in 50 l of methanol and analyzed by LC-MS/MS.
Fragmentationswere performed in the LTQ ion trapwith collision energy of 30 eV, and the resultant fragment ionswere detected inOrbitrapwith amass
resolution of 30,000 at m/z 400 and a mass accuracy within 5 ppm. MS2 spectra of parent ion [M-2H]2 at m/z 731 (corresponding 18:2–18:2–18:2–
18:2-CL-OH) (C), parent ion [M-2H]2 atm/z 739 (corresponding 18:2–18:2–18:2–18:2-CL-OOH) (D), and parent ion [M-2H]2 atm/z 755 (correspond-
ing 18:2–18:2–18:2–22:6-CL-OH) (E) are shown here.
iPLA2 hydrolyzes oxidized cardiolipin
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performed, and the released oxidized fatty acids were analyzed
by charge-switch derivatization, LC-MS/MS, and accurate
mass product ion analysis. The oxidized fatty acids released
from cardiolipin by iPLA2 were 9-HODE and 13-HODE (Fig.
6A). Intriguingly, the selectivity of iPLA2 for 9-HODE release
in this system is significantly higher than that of 13-HODE. To
determine if this difference is due to differences in substrate
content of 9-HODE versus 13-HODE, or due to selectivity of
iPLA2 for discrete oxidized aliphatic chains, each substrate
was completely hydrolyzed by phospholipase A1 from T.
lanuginosus and phospholipase A2 from porcine pancreas. The
released fatty acids were analyzed as described under “Experi-
mental procedures.” That the amounts of 9-HODE and
13-HODE were the same when all aliphatic chains were hydro-
lyzed (Fig. 6B) indicates that iPLA2 preferentially hydrolyzes
9-HODE in comparison to 13-HODE from oxCL in bilayer
systems.
Hydrolysis of oxidized cardiolipin bymitochondrial iPLA2
To examine the ability of iPLA2 to hydrolyze oxidized car-
diolipins inmitochondria, we isolatedmitochondria fromwild-
type and iPLA2/ mice liver tissue. Mitochondria were
briefly sonicated and incubated with oxidized TLCL (prepared
by cytochrome c treatment) or ethanol vehicle-only in the pres-
ence of calcium. Although the catalytic activity of purified
recombinant human iPLA2 (63 kDa) is calcium-independent,
we have previously demonstrated that mitochondrial mem-
brane-associated iPLA2 isoforms can be dramatically acti-
vated by either calcium or magnesium ion, which we have pre-
viously ascribed to the complexing of the divalent cations with
the phospholipid acyl chain carbonyl group facilitating hydro-
lysis (41). The production of oxidized linoleic acids including
9-HODE, 13-HODE, 9(10)-DiHOME, and 12(13)-DiHOME
were measured as described under “Experimental procedures.”
Comparedwithwild-typemitochondria homogenate, iPLA2/
mitochondria released significantly less 9-HODE, 9(10)-
DiHOME, and 12(13)-DiHOME when incubated with exoge-
nous oxCL (Fig. 7, A and B). In addition, only small amounts of
oxidized linoleic acids were released inmitochondrial homoge-
nates without oxCL proving that the production of oxidized
linoleic acids was mainly due to the hydrolysis of exogenous
oxCL in samples containing oxCL in these in vitro experiments
with homogenized mitochondria.
Similar experiments were also performedwithmitochondria
isolated from wild-type and cardiac myocyte-specific iPLA2
transgenic mice heart tissue. Compared with wild-type
mitochondria homogenates, iPLA2 transgenic mitochondria
homogenates released significantly more 9-HODE, 9(10)-
DiHOME, and 12(13)-DiHOME (Fig. 7, C–D). However, the
production of 13-HODE was the same between wild-type and
transgenic mitochondrial homogenates. This selectivity is con-
sistent with the results obtained with purified recombinant
iPLA2. In addition, iPLA2 transgenic mitochondria homoge-
nates also hydrolyzedmore oxidized cardiolipin comparedwith
that of wild-type (Fig. 7E).
Genetic ablation of iPLA2 resulted in the accumulation of
oxidized cardiolipins in intact mitochondria subjected to
oxidative stress
To determine if iPLA2 is responsible for hydrolyzing the
majority of oxidized cardiolipin produced by mitochondria
under oxidative stress, we isolated intact mitochondria from
WT and iPLA2/ myocardium as described under “Experi-
mental procedures.” Intactmitochondriawere subjected to oxi-
dative stress by incubation in buffer containing 2 mM ADP, 0.3
mM NADPH, and 0.012 mM Fe3 for 15 min. The ADP/NA-
DPH/Fe3 system has previously been shown to effectively
induce oxidative stress and lipid peroxidation (42, 43).Oxidized
linoleic acid and oxidized cardiolipins were analyzed as
described under “Experimental procedures.” The accumulation
of oxidized cardiolipins in iPLA2/ mitochondria during
oxidative stress was 4 times greater than that in wild-typemito-
chondria (Fig. 8A). In contrast, the release of oxidized linoleic
acid from wild-type mitochondria is significantly higher than
that in iPLA2/ mitochondria during oxidative stress (Fig.
8B). These results are consistent with the notion that iPLA2
has a major role in hydrolysis of oxidized cardiolipin aliphatic
chains during oxidative stress in intactmitochondria to directly
release bioactive lipid 2nd messengers.
Discussion
The results of the present study identify mitochondrial
iPLA2 as the enzymic mediator of the hydrolysis of oxidized
aliphatic chains in oxCL molecular species leading to the di-
rect release of oxidized fatty acid lipid 2nd messengers in the
mitochondrial compartment. Moreover, we demonstrate that
negatively charged cardiolipin markedly activates iPLA2
phospholipase activity on arachidonic acid containing choline
glycerophospholipids, thereby integrating the production of
signaling molecules from discrete phospholipid pools (e.g. cho-
line glycerophospholipids versus oxCLs). Thus, the present
Figure 5. Identification of the oxidized fatty acyl chains in oxidized car-
diolipin from mouse myocardial tissue. Lipids extracts from mouse myo-
cardial tissue were first purified using an aminopropyl solid phase extraction
column, and the oxidized cardiolipin was then separated by a C18 HPLC col-
umn. The purified oxidized cardiolipin was then completely hydrolyzed by
porcine pancreas PLA2 and T. lanuginosus PLA1, derivatized with AMPP, and
analyzed by LC-MS/MS. The left panel displays the transitions of the detected
oxidized fatty acids in thehydrolyzedoxidizedcardiolipin sample,whichhave
identical retention times as authentic standards (right panel).
iPLA2 hydrolyzes oxidized cardiolipin
J. Biol. Chem. (2017) 292(25) 10672–10684 10677
 at W
ashington U









study identifies an integrated signaling network in mitochon-
dria mediated by iPLA2 that participates in the integration of
cellular bioenergetics and signaling.
Because CL composes5–20% of the phospholipid content
of the inner mitochondria membrane (6), cardiolipin-induced
activation ofmitochondrial iPLA2phospholipid hydrolysis is a
likely regulator of the release of polyunsaturated fatty acids (i.e.
AA and DHA) and lysophospholipids from glycerophospholip-
ids in the mitochondrial membrane. Both AA and AA-LPC
released from phosphatidylcholine by iPLA2 can serve as sub-
strates for oxidized lipid 2nd messenger synthesis, which is
underscored by the work we published previously showing the
utilization of 2-AA-LPC by cyclooxygenase-2 to generate 2-ei-
cosanoid lysolipids (40). It has been previously demonstrated
that robust losses of cardiolipin content occurs in pathologic
conditions including diabetes (21), heart failure (45), and can-
cer (46). The depletion of cardiolipin in those pathological pro-
cesses likely reduces the hydrolysis of mitochondrial mem-
brane phospholipid by iPLA2 followed by decreased synthesis
of oxidized lipid 2nd messengers precipitating maladaptive
alterations in the interplay of these two integrated signaling
pathways.
Through the use of high mass accuracy high resolution mass
spectrometry, we identified three types of oxidized cardiolipin
molecular species in mouse myocardial tissue. These include
hydroxylated linoleic acid, hydroxylated docosahexaenoic acid,
and linoleic acid hydroperoxide. We also identified the molec-
ular species of oxidized fatty acids in cardiolipin as 9-HODE,
13-HODE, 10-HDHA, and 11-HDHA by hydrolysis, charge-
switch AMPP derivatization, and high mass accuracy analysis
of product ions. Furthermore, with purified recombinant
iPLA2 and cardiac myocyte-specific transgenic expression of
iPLA2, we demonstrated that 9-HODE is preferentially hydro-
lyzed in comparison to 13-HODE from oxidized CL by iPLA2.
To substantiate the role of iPLA2 in the content of oxidized
CL molecular species in vivo, we compared the amount of oxi-
dized CL in WT versus iPLA2/ hearts. Notably, KO of
iPLA2 resulted in the accumulation of oxidized CL molecular
species in the heart. The accumulation of oxidized CLs estab-
lishes a primary role for iPLA2 in the release of oxidized ali-
Figure 6. Recombinant human iPLA2 selectively hydrolyzed 9-HODE, but not 13-HODE, from oxidized TLCL. A, specific activity of iPLA2 hydrolysis of
oxidized cardiolipin. Purified recombinant iPLA2 (2.5 g) was incubated with 6 M TLCL, 6 M oxTLCL (fraction 1 from HPLC purification of oxCL), and 48 M
PAPC at 37 °C for 10 min in 20 mM HEPES, pH 7.2, containing 2 mM EGTA and 1mM DTT. The products including 9-HODE, 13-HODE, and linoleic acid (LA) were
extracted in the presence of internal standards (d4-16:0 FFA, 13-HODE-d4), derivatized with AMPP, and analyzed by LC-MS/MS. B, relative amounts of 9-HODE,
13-HODE, and LA in TLCL/oxTLCL/PAPC vesicles after complete hydrolysis by porcine pancreas PLA2 and T. lanuginosus PLA1, derivatization with AMPP, and
analysis by LC-MS/MS. C–E, oxidized cardiolipin used as substrate for iPLA2 hydrolysis was prepared by cytochrome c-mediated oxidation in the presence of
hydrogenperoxide as describedpreviously (52) andpurifiedby reversed-phaseHPLC (C). Fraction 1 (D) and fraction 2 (E) containingoxTLCLwere collected and
analyzedbymass spectrometry as describedunder “Experimental procedures.” Values are the averageof three independent preparations S.E. ***,p 0.001.
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phatic chains from CLs in vivo. This result is consistent with
those of Kagan and co-workers (30) indicating iPLA2 likely
released oxidized aliphatic chains from CL in vivo as deter-
mined by use of R-BEL.
To determine the effects of oxidative stress on cardiolipin
oxidation and the major role of iPLA2, we utilized a well
accepted system to produce oxidative stress in intactmitochon-
dria (39, 40). Treatment of WT mitochondria with NADPH,
ADP, and Fe3 resulted in the robust production of 12(13)-
DiHOMEand 9(10)-DiHOMEwith lesser amounts ofmonohy-
droxylated species including 9-HODE and 13-HODE. Remark-
ably, mitochondria isolated from iPLA2/ mice exhibited a
70% reduction in both DiHOME and HODE production under
oxidative stress, demonstrating the importance of iPLA2 in
the release of oxidized fatty acid lipid 2nd messengers of signal
transduction during oxidative stress.
In heart or liver mitochondria, 5–20% of mitochondrial
membrane lipids are cardiolipin, and70% of fatty acyl chains
in cardiolipin are linoleic acid (6). Therefore, cardiolipinmay be
a major source of oxidized linoleic acid second messengers. In
this study we have established that the generation of oxidized
linoleic acid from oxidized cardiolipin under oxidative stress is
regulated by iPLA2, substantiating the indispensable role of
iPLA2 in the production of oxidized linoleic acid lipid second
messengers from oxCL in mitochondria.
Previous studies have demonstrated that oxidized linoleic
acids have pivotal roles in multiple pathological processes,
including inflammatory hyperalgesia and the activation of G
protein-coupled receptor G2A (47–50). For example, Patward-
han et al. (47), Green et al. (49), and Alsalem et al. (48) have
shown that oxidized linoleic acids can activate the TRPA1
receptor and contribute to inflammatory hyperalgesia and allo-
dynia after injury. In addition, Obinata et al. (50) demonstrated
that 9-HODE is a ligand for the G protein-coupled receptor
G2A that increasesmobilization of intracellular calcium in cells
expressing this receptor. Because iPLA2 is a major enzymic
mediator of oxidized linoleic acid lipid 2nd messenger release,
it seems likely that iPLA2 is involved in these processes.
In conclusion, this study provides robust evidence that
iPLA2 is the major enzyme mediating the release of oxidized
aliphatic chains from oxCLs. This process likely servesmultiple
roles through 1) the release of lipid 2nd messengers that medi-
Figure 7. Oxidized linoleic acid production and oxidized cardiolipin consumption in wild-type, iPLA2
/, and cardiac myocyte-specific iPLA2
transgenicmitochondrial homogenates in thepresenceof exogenousoxTLCL.A and B, mitochondriawere isolated fromwild-type and iPLA2
/mouse
liver and homogenized by sonication. Mitochondria homogenates (1 mg protein/ml) were incubated with 20 M oxTLCL or ethanol vehicle alone at 37 °C for
15 min. The reactions were terminated by the addition of methanol (25% total volume) containing internal standards (13-HODE-d4, 12(13)-DiHOME-d4). The
released oxidized fatty acids were purified by reversed phase solid phase extraction, derivatized with AMPP, and finally analyzed by LC-MS/MS. C and D, the
same experiments were performed with heart mitochondria isolated fromwild-type and cardiac myocyte specific iPLA2 transgenic mice. E, heart mitochon-
driawere isolated fromwild-type and cardiacmyocyte-specific iPLA2 transgenicmice.Mitochondria homogenates (1mgprotein/ml)were incubatedwith 20
M oxTLCL or ethanol vehicle alone at 37 °C for 15 min. The reactions were terminated by adding chloroform/methanol 1:1 (v/v) in the presence of TMCL
internal standard. The chloroformphasewas separated, dried, and redissolved in chloroform. Theoxidized cardiolipinwaspurifiedby aminopropyl solid phase
extraction column and analyzed by LC-MS/MS in the negative ion mode. The results here show the consumption of oxidized cardiolipin per mg of protein in
30-min incubations. Values are the average of three independent preparations S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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ate mitochondrial signaling and bioenergetics and 2) the
removal of pathologic products of oxidative stress which com-
promises mitochondrial bioenergetic function. Moreover, we
demonstrate the profound activation of iPLA2 by cardiolipin,
which facilitates the release of polyunsaturated fatty acids from
PC for the downstream production of signaling metabolites.
Collectively, the direct release of oxidized linoleic acid lipid 2nd
messengers from CL in the mitochondrial compartment and
iPLA2-catalyzed AA and 2-AA LPC release from choline glyc-
erophospholipids are integrated processes for the generation of
lipid 2nd messengers in the mitochondrial compartment from
discrete phospholipid precursor pools.
Experimental procedures
Materials
Tetralinoleoyl cardiolipin and 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphocholine were purchased from Avanti
Polar Lipids (Alabaster, AL). Kinetex 5-m EVO C18 columns
(250	 4.6 mm and 150	 2.1 mm) were purchased from Phe-
nomenex (Torrance, CA). Ascentis Express 2.7-m C18 col-
umn (150	 2.1 mm) was purchased from Supelco (Bellefonte,
PA). Strata-X solid phase extraction cartridges (30 mg/1 ml)
were purchased from Phenomenex. Aminopropyl solid phase
extraction cartridges (50 mg/1 ml) were purchased from
Supelco (Bellefonte, PA). HPLC grade acetonitrile and chloro-
formwere purchased fromBurdick & Jackson (Muskegon,MI).
HPLC grade methanol and water were purchased from Fisher.
The AMPP derivatization kit, ()-9-hydroxy-10E,12Z-octa-
decadienoic acid, ()-13-hydroxy-9Z,11E-octadecadienoic




tadecadienoic-9,10,12,13-d4 acid, and ()12,13-dihydroxy-9Z-
octadecenoic-9,10,12,13-d4 acid were purchased from Cayman
Chemical (Ann Arbor, MI). Leupeptin, aprotinin, and glycerol
were purchased from Fisher. All other chemicals were pur-
chased from Sigma.
General animal studies
Animal protocols were conducted in strict accordance with
the National Institutes of Health guidelines for humane treat-
ment of animals and were reviewed and approved by the Ani-
mal Studies Committee of Washington University.
Expression and purification of iPLA2(His)6 in Sf9 cells
Recombinant iPLA2 was purified as previously described
(51). Briefly, 100 ml of Sf9 cells (1 	 106 cells/ml) were trans-
fected with recombinant baculovirus encoding iPLA2(His)6 at
a multiplicity of infection of 1. After 48 h, the cell suspension
was centrifuged at 300 	 g for 10 min, and the cell pellet was
resuspended in 10 ml of lysis buffer (25 mM potassium phos-
phate, pH 7.8, containing 20% glycerol, 1 mM imidazole, 2 mM
2-mercaptoethanol, 5g/ml leupeptin, and 5g/ml aprotinin).
Cells were lysed by sonication (20 pulses of 1 s at 30% power)
and centrifuged at 100,000	 g for 45min. The supernatant was
mixed with an equal volume of dilution buffer (25 mM potas-
sium phosphate, pH 7.8, containing 20% glycerol, 1 mM imid-
azole, 500 mM sodium chloride, and 2 mM 2-mercaptoethanol)
and loaded onto a 5-ml column of HIS Select Cobalt Affinity
Gel previously equilibrated with 25 mM potassium phosphate,
pH 7.8, containing 20% glycerol, 1 mM imidazole, and 250 mM
sodium chloride. The column was washed with 10 column vol-
umes of 25mM potassium phosphate buffer, pH 7.8, containing
20% glycerol, 10 mM imidazole, 500 mM sodium chloride, and 1
mM 2-mercaptoethanol. Recombinant iPLA2(His)6 (63 kDa)
was eluted with 25 mM potassium phosphate, pH 7.8, contain-
ing 20% glycerol, 200 mM imidazole, 500 mM sodium chloride,
and 1mM2-mercaptoethanol. Purified iPLA2was flash-frozen
in liquid N2 and stored at80 °C.
Preparation of oxidized cardiolipin
Oxidized cardiolipinwas prepared as described byKagan and
co-workers (30). Briefly, TLCL (250 M) was resuspended in
buffer (20 mM HEPES, pH 7.4, 100 M diethylenetriaminepen-
taacetic acid (DTPA)) by sonication (5 min, 1-s pulse, 30%
power). Cytochrome c andH2O2were added, and samples were
incubated for 1 h at 37 °C. Cytochrome c and H2O2 were added
at 10-min intervals (6 additions total), and the final concentra-
tions of cytochrome c and H2O2 were 10 M and 100 M,
respectively. Oxidized CL was extracted by adding two vol-
umes of chloroform/methanol (1:1, v/v). The chloroform phase
Figure8.Accumulationof oxidized cardiolipin (A) andproductionof oxi-
dized linoleic acids (B) in intact wild-type and iPLA2
/ mitochondria
stimulated by oxidative stress. Myocardial mitochondria were isolated
from wild-type and iPLA2
/ mice and reconstituted in isotonic buffer.
Intact mitochondria (0.8 mg/ml) were incubated with 2 mM ADP, 0.3 mM
NADPH, 0.012 mM Fe3, and 2.5 mM phosphate at 37 °C for 15 min. The reac-
tions were terminated by adding chloroform/methanol (1:1, v/v). The chloro-
form phase was separated and dried under a nitrogen stream. A, for analysis
of oxidized cardiolipin, the dried residues were redissolved in chloroform,
purifiedby aminopropyl solid phase extraction, andanalyzedby LC-MS/MS in
the negative ion mode. B, for analysis of oxidized linoleic acids (oxLAs), the
dried residues were redissolved in water/methanol 4:1, purified by reversed
phase solid phase extraction, derivatized with AMPP, and finally analyzed by
LC-MS/MS in the positive ion mode. Values are the average of four indepen-
dent preparations S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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was separated and dried under N2 stream. The dried residue
was dissolved in methanol and loaded on a C18 reverse phase
HPLC column (Kinetex EVO C18, 5 m, 250-mm	 4.6 mm).
The columnwas eluted at a flow rate of 1 ml/min. A gradient of
solvent A (acetonitrile/methanol/10 mM ammonium acetate in
water, pH7.5, 2:1:1, v/v/v) and solvent B (methanol) was used as
follows: 0 min, 50% B; 5 min, 50% B; 20 min, 100% B; 27 min,
100% B; 27.1 min, 50% B; 35 min, 50% B. Fractions of eluent
containing oxCL were collected and dried under a nitrogen
stream. The dried residue was extracted by chloroform/
methanol/water (1:1:1, v/v/v) to eliminate ammonium ace-
tate and analyzed by mass spectrometry.
Hydrolysis of cardiolipin/phosphatidylcholine by purified
recombinant iPLA2
Small unilamellar vesicles (SUVs) containing either TLCL or
18:2–18:2–18:2 monolysocardiolipin as guest in PAPC host
vesicles were prepared by sonicating (30% power, 1-s pulse, 5
min) TLCL and PAPC in HEPES buffer (20 mMHEPES, pH 7.2,
2mM EGTA, 1mMDTT). 18:2–18:2–18:2monolysocardiolipin
was prepared and purified as described previously (52). The
concentrations of the phospholipid substrates were specified
under “Results.” The reaction was initiated by the addition of
purified recombinant iPLA2 to the SUVs in HEPES buffer and
incubated at 37 °C for 10 min. The reaction was terminated by
adding 2 volumes of chloroform/methanol (1:1, v/v) containing
TMCL (tetramyristoyl cardiolipin) and d4-16:0 fatty acid inter-
nal standards. The chloroform phase was separated and dried
under a nitrogen stream. The dried residue was resuspended in
methanol and used for LC-MS/MS analysis.
For the oxidized cardiolipin hydrolysis reaction, the SUV
containing 6 M TLCL and 6 M oxTLCL (fraction 1 from
HPLC purification of oxCL) was prepared, and the reaction
with purified recombinant iPLA2 was performed the same as
for the nonoxidized cardiolipin except that the reaction was
terminated by adding methanol (to 20% final volume) contain-
ing 13-HODE-d4, 12(13)-DiHOME-d4, and d4-16:0 fatty acid
internal standards before solid phase extraction.
Solid phase extraction and AMPP derivatization of oxidized
fatty acids
Solid phase extraction of fatty acids and oxidized fatty acids
was performed using a Strata-X reversed phase cartridge (Phe-
nomenex, 30 mg/1 ml). The cartridges were prewashed with 2
ml of methanol and then equilibrated with 80% H2O, 20%
methanol. The samples were applied to the cartridge, and the
cartridges were washed with 2 ml of solvent containing 90%
H2O, 10%methanol. Oxidized fatty acids were eluted with 1ml
of methanol and dried under nitrogen stream.
AMPP derivatization was performed as described by Gelb
and co-workers (53). In brief, 20 l of cold acetonitrile/N,N-
dimethylformamide (4:1, v/v) was added to the dried residue.
The sample tube was vortexed, then 20l of cold 640mMN-(3-
dimethylaminopropyl)-N
-ethylcarbodiimide in water, 10l of
20 mM 1-hydroxybenzotriazole in acetonitrile/dimethylforma-
mide (99:1 v/v), and 30 l of N-(4-aminomethylphenyl)-pyri-
dinium (AMPP) in acetonitrile were added and vortexed. After
30 min of incubation at 60 °C, the sample was cooled to room
temperature and subjected to LC-MS/MSanalysis as previously
described (54).
Analysis of oxidized cardiolipin in flash-frozenWT and
iPLA2
/myocardium
The iPLA2/ mouse was generated in our laboratory as
described previously (35). After euthanasia of wild-type or
iPLA2/ mice by cervical dislocation, hearts were removed
and quickly rinsed with phosphate-buffered saline, blotted, and
flash-frozen in liquid nitrogen. Frozenheart tissuewas stored in
liquid nitrogen vapor (180 °C) until extraction. To perform
extractions, 50 mg of heart tissue were added into the test
tubes with 2 ml of chloroform:methanol (2:1 v/v with 1% acetic
acid, 2 l of an antioxidant mixture (0.2 mg/ml butylated
hydroxytoluene, 2 mg/ml triphenylphosphine, 0.2 mg/ml
EDTA, and 2 mg/ml indomethacin in methanol:ethanol:water,
2:1:1, v/v/v) and 0.1 nmol/mg of protein tetramyristoyl cardio-
lipin internal standard. The tissue was then homogenized using
a Polytron homogenizer followed by the addition of 0.6 ml of
0.9% sodium chloride aqueous solution. The mixture was thor-
oughly vortexed and then centrifuged at 15,000	 g for 10 min.
The chloroform layer was separated, and the aqueous phase
was extracted again with 1.2 ml of chloroform. The chloroform
phases were combined, dried under a stream of nitrogen, and
resuspended in 1.5ml of chloroform for subsequent aminopro-
pyl solid phase extraction.
The oxidized cardiolipins in the crude extracts were purified
using an aminopropyl solid phase extraction column as
described before (44). Briefly, the aminopropyl solid phase
extraction column was equilibrated with 1 ml of hexane before
loading 200 l of extract in chloroform onto the column. The
column was washed with 0.5 ml of chloroform and 2 ml of
methanol. Oxidized cardiolipins were eluted by 1 ml of chloro-
form/methanol (4:1, v/v) containing 0.2 M ammonium acetate.
The eluent was dried under a nitrogen stream, resuspended in
0.2 ml of methanol, and analyzed by LC-MS/MS.
For MS2 analysis of oxidized cardiolipin, the lipid extract
from two wild-type hearts was first purified by an aminopropyl
solid phase extraction column then separated on C18 HPLC
column (Kinetex EVO C18, 5 m, 250 mm 	 4.6 mm) as
described above. The oxidized cardiolipin fraction was col-
lected, dried under a nitrogen stream, and reconstituted in 50
l of methanol for LC-MS/MS analysis.
To examine the identities of the oxidized fatty acyl chains in
oxidized cardiolipin frommousemyocardium, oxidized cardio-
lipins from two mouse hearts were purified by C18 HPLC and
then resuspended by sonication in 1ml ofHEPES buffer (20mM
HEPES, pH 7.4, 10% glycerol, 2 mM calcium, 1 mM DTT) fol-
lowed by the addition of 10 l of phospholipase A2 from por-
cine pancreas and 10 l of phospholipases A1 from T. lanugi-
nosus. The reaction was incubated at 37 °C for 30 min. The
oxidized fatty acids were purified, derivatized, and analyzed as
described above.
LC-MS/MS analysis
LC-MS/MS analysis was performed using an LTQ Orbitrap
mass spectrometer connected to a Surveyor HPLC system.
AMPP-derivatized oxidized fatty acids were separated with a
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C18 reverse phase column (Ascentis Express C18 2.7 m,
150 	 2.1 mm) at 22 °C with a flow rate of 200 l/min. The
linear gradient of solvent A (water with 10 mM ammonium
acetate, pH 4.3) and solvent B (acetonitrile) was used as follows:
0 min, 25% B; 5 min, 25% B; 20 min, 95% B; 27 min, 95% B; 27.1
min, 25%B; 35min, 25%B. The sample injection volumewas 10
l, and the autosampler tray temperature was set as 4 °C. The
spray voltage in electrospray ionization source was 4.1 kV. The
sheath gas flow rate was 40. The capillary temperature was
270 °C. TheAMPP-derivatized oxidized fatty acidwas analyzed
with selected reaction monitoring. The collision energy used
was 30 eV with an isolation width of1.5 thomson.
Oxidized cardiolipin molecular species were separated using
a C18 reversed phase column (Kinetex EVO C18, 5 m, 150	
2.1 mm) at 22 °C with a flow rate of 200 l/min. A linear gradi-
ent of solventA (acetonitrile/methanol/10mMammoniumace-
tate in water, pH 7.5, 2:1:1, v/v/v) and solvent B (methanol) was
used as follows: 0 min, 50% B; 5 min, 50% B; 20 min, 100% B;
27 min, 100% B; 27.1 min, 50% B; 35 min, 50% B. The sample
injection volume was 10 l, and the autosampler tray tem-
perature was set as 4 °C. The electrospray ionization condi-
tions were the same as those used in the analysis AMPP-
derivatized oxidized fatty acids. For MS2 analysis of oxidized
cardiolipin, the collision energy was 30 eV, and the isolation
width was  2 Th.
Isolation and incubation ofmitochondria
Cardiac myocyte-specific iPLA2 transgenic and iPLA2/
mice were generated in our laboratory as described previously
(35, 36). After euthanasia by cervical dislocation, hearts and
livers were removed and washed extensively in ice-cold mito-
chondrial isolation buffer (10mMHEPES, 0.25 M sucrose, 1 mM
EGTA, 0.4% fatty acid-free BSA, pH7.4) and finelyminced. The
tissues were then homogenized on ice with a 10-ml Teflon pes-
tle tissue grinder (12 strokes for heart and 8 strokes for liver at
speed 15). The homogenates were first centrifuged at 700 	 g
for 10min to pellet nuclei and cellular debris. The supernatants
were centrifuged at 10,000 	 g for 10 min to pellet mitochon-
dria. The mitochondrial pellets were resuspended in isolation
buffer and centrifuged again at 10,000	 g. The mitochondrial
pellets were briefly rinsed with BSA- and EGTA-free isolation
buffer and reconstituted in buffer as indicated under the differ-
ent experimental conditions.
For exogenous oxidized cardiolipin hydrolysis experiments,
liver mitochondria from iPLA2/ and wild-type mice were
reconstituted in ice-cold HEPES buffer (10 mM HEPES, 10%
glycerol, 2mMDTT, pH7.4) and sonicated (5 pulses of 1 s at 30%
power). The concentration ofmitochondrial protein was deter-
mined by a Bradford protein assay (Bio-Rad). The oxidized
tetralinoleoylcardiolipin was delivered in ethanol (20 nmol of
oxCL/mg protein with a final concentration of ethanol at 2%).
The mitochondrial homogenate containing oxidized cardiolip-
ins or vehicle alone was sonicated again (5 pulses of 1 s, 30%
power). Hydrolysis of oxidized cardiolipins was initiated by the
addition of CaCl2 (2 mM) and incubation at 37 °C for 15 min.
Reactions were terminated by adding methanol (20% total vol-
ume) containing internal standards (13-HODE-d4, 12(13)-
DiHOME-d4). The released oxidized fatty acids were purified
by reversed phase solid phase extraction, derivatized with
AMPP, and finally analyzed by LC-MS/MS as described above.
The same experiments were performed with heart mitochon-
dria isolated from wild-type and heart-specific iPLA2 trans-
genic mice.
To measure the consumption of oxidized cardiolipin, the
reactions were terminated by adding chloroform/methanol
(1:1, v/v) in the presence of TMCL internal standard. The chlo-
roform phase was separated, dried, and redissolved in chloro-
form. The oxidized cardiolipin was purified by aminopropyl
solid phase extraction and analyzed by LC-MS/MS in negative
ion mode.
For intact mitochondrial oxidation experiments, liver mito-
chondria from wild-type and iPLA2/ mice were reconsti-
tuted in ice-cold isotonic buffer (75 mM Tris-Cl, 5 mM HEPES,
pH 7.4, 60 mM KCl, 12.5 mM sucrose, 0.5 mM MgCl2, 2.5 mM
KH2PO4). The concentration of mitochondrial protein was
determined by a Bradford protein assay and diluted with buffer
to a final concentration of 0.8 mg/ml. Oxidative stress was ini-
tiated by adding 2 mM ADP, 0.3 mM NADPH, 0.012 mM Fe3,
and subsequently incubation at 37 °C for 15min. Oxidized fatty
acids and oxidized cardiolipins were extracted, purified, and
analyzed as described above.
Statistical analyses
Results are expressed as averages  S.E. The significance of
results was determined by Student’s t test, and results were
considered significant at a level of p 0.05.
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M. L. performed the preliminary experiments. S. G. andH. F. S. gen-
erated and provided iPLA2/ and cardiac myocyte-specific
iPLA2 transgenic mice. G.-Y. L. conducted the experiments and
performed the mass spectrometric analyses. G.-Y. L., R. W. G.,
S. H. M., andC. M. J. analyzed the data and prepared themanuscript.
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